See more : Gujarat Gas Limited (GUJGASLTD.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Immunocore Holdings plc (IMCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunocore Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Macatawa Bank Corporation (MCBC) Income Statement Analysis – Financial Results
- Inflection Point Acquisition Corp. II (IPXX) Income Statement Analysis – Financial Results
- TV18 Broadcast Limited (TV18BRDCST.BO) Income Statement Analysis – Financial Results
- Casa Systems, Inc. (CASA) Income Statement Analysis – Financial Results
- MedRx Co., Ltd (4586.T) Income Statement Analysis – Financial Results
Immunocore Holdings plc (IMCR)
About Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 249.43M | 143.74M | 26.52M | 30.11M | 25.67M | 23.65M |
| Cost of Revenue | 1.04M | 454.00K | 73.23M | 74.81M | 99.99M | 0.00 |
| Gross Profit | 248.39M | 143.28M | -46.71M | -44.70M | -74.32M | 23.65M |
| Gross Profit Ratio | 99.58% | 99.68% | -176.12% | -148.42% | -289.54% | 100.00% |
| Research & Development | 163.55M | 89.17M | 73.23M | 74.81M | 99.99M | 83.58M |
| General & Administrative | 0.00 | 0.00 | 88.40M | 45.74M | 44.18M | 34.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 99.99M | 83.58M |
| SG&A | 144.50M | 93.72M | 88.40M | 45.74M | 44.18M | 34.16M |
| Other Expenses | 0.00 | -3.00K | 57.00K | -1.15M | 185.00K | 5.60M |
| Operating Expenses | 308.04M | 182.89M | 161.68M | 119.40M | 144.17M | 117.73M |
| Cost & Expenses | 309.08M | 183.34M | 161.68M | 119.40M | 144.17M | 117.73M |
| Interest Income | 17.99M | 3.15M | 47.00K | 706.00K | 1.40M | 822.00K |
| Interest Expense | 5.15M | 7.69M | 5.81M | 3.11M | 3.80M | 842.00K |
| Depreciation & Amortization | 4.09M | 5.34M | 7.59M | 8.98M | 9.21M | 6.71M |
| EBITDA | -51.65M | -38.35M | -166.72M | -102.59M | -113.18M | -86.75M |
| EBITDA Ratio | -20.71% | -25.36% | -509.48% | -250.54% | -419.63% | -342.21% |
| Operating Income | -59.65M | -39.61M | -135.16M | -86.19M | -118.32M | -93.46M |
| Operating Income Ratio | -23.91% | -27.56% | -509.66% | -286.22% | -460.95% | -395.09% |
| Total Other Income/Expenses | -1.24M | 5.79M | 33.66M | -1.17M | -7.87M | 5.28M |
| Income Before Tax | -60.89M | -44.15M | -140.93M | -87.36M | -126.19M | -88.18M |
| Income Before Tax Ratio | -24.41% | -30.71% | -531.40% | -290.10% | -491.60% | -372.78% |
| Income Tax Expense | -5.60M | -2.92M | -9.41M | -13.27M | -22.26M | -16.55M |
| Net Income | -55.29M | -41.22M | -131.52M | -74.09M | -103.93M | -71.63M |
| Net Income Ratio | -22.17% | -28.68% | -495.94% | -246.04% | -404.89% | -302.82% |
| EPS | -1.13 | -0.90 | -3.10 | -2.33 | -3.81 | -2.62 |
| EPS Diluted | -1.13 | -0.90 | -3.00 | -2.33 | -3.81 | -2.62 |
| Weighted Avg Shares Out | 48.89M | 45.71M | 42.49M | 31.78M | 27.31M | 27.31M |
| Weighted Avg Shares Out (Dil) | 48.89M | 45.71M | 43.86M | 31.78M | 27.31M | 27.31M |
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
Immunocore Holdings PLC Sponsored ADR (IMCR) is Attracting Investor Attention: Here is What You Should Know
Immunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on It
Immunocore to present four posters at AACR Annual Meeting 2023
Immunocore Holdings plc (IMCR) Q4 2022 Earnings Call Transcript
Is a Surprise Coming for Immunocore (IMCR) This Earnings Season?
Immunocore to present at upcoming investor conferences
Immunocore Holdings: A Meteoric Rise Likely Here To Stay
Investors Heavily Search Immunocore Holdings PLC Sponsored ADR (IMCR): Here is What You Need to Know
Source: https://incomestatements.info
Category: Stock Reports